CA
NZ
UK
AU
IND
US
…
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducing the incidence of age-related diseases. Its lead drug candidate is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-1003, a topical delivery of SIRT6 to the fibroblasts in the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005, which addresses mitochondrial dysfunction observed in sarcopenia for muscle health and combat sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company has collaborative research agreements with Revatis SA and EXO Biologics for therapy medicinal products. Genflow Biosciences plc was founded in 2020 and is headquartered in London, the United Kingdom.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2021-03-31 |
| Income before tax | -1.59M | -1.63M | -1.34M | -0.99M | - |
| Net income | -1.59M | -1.63M | -1.34M | -0.99M | - |
| Selling general administrative | 1.81M | 1.80M | 0.50M | 0.53M | - |
| Selling and marketing expenses | 0.10M | 0.96M | 0.17M | 0.14M | - |
| Gross profit | -0.00M | -0.00M | - | - | - |
| Reconciled depreciation | 0.00M | 0.00M | 0.00M | - | - |
| Ebit | -1.59M | -1.80M | -1.33M | -0.64M | -0.65M |
| Ebitda | -1.59M | -1.80M | -1.33M | -0.99M | - |
| Depreciation and amortization | 0.00M | 0.00M | 0.00M | - | - |
| Operating income | -1.27M | -1.80M | -1.33M | -0.99M | - |
| Other operating expenses | 1.27M | 1.80M | 1.33M | 0.94M | 0.05M |
| Interest expense | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Net interest income | 0.00M | 0.00M | -0.00M | -0.00M | - |
| Income tax expense | - | -0.00M | 0.00M | 0.00M | - |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Total operating expenses | 1.91M | 1.80M | 1.33M | 0.94M | - |
| Cost of revenue | 0.00M | 0.00M | - | - | - |
| Total other income expense net | -0.32M | 0.17M | -0.00M | -0.00M | - |
| Net income from continuing ops | -1.59M | -1.63M | -1.34M | -0.99M | - |
| Net income applicable to common shares | - | - | - | -1.08M | -0.65M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2021-03-31 |
| Total assets | 0.39M | 1.07M | 2.62M | 0.28M | - |
| Other current assets | 0.07M | 0.04M | - | 0.05M | - |
| Total liab | 0.79M | 0.35M | 0.25M | 0.22M | - |
| Total stockholder equity | -0.40M | 0.73M | 2.37M | 0.06M | - |
| Other current liab | 0.42M | -0.16M | 0.17M | 0.18M | - |
| Common stock | 0.10M | 0.09M | 0.09M | 0.07M | 0.00M |
| Capital stock | 0.10M | 0.09M | 0.09M | 0.07M | - |
| Retained earnings | -5.59M | -3.60M | -2.14M | -0.81M | -0.11M |
| Cash | 0.28M | 0.68M | 2.36M | 0.22M | - |
| Total current liabilities | 0.79M | 0.35M | 0.25M | 0.22M | 0.06M |
| Net debt | -0.28M | -0.68M | -2.36M | -0.22M | - |
| Other stockholder equity | 4.83M | 4.19M | 4.42M | 0.79M | 0.07M |
| Total current assets | 0.38M | 1.07M | 2.62M | 0.28M | 0.28M |
| Net tangible assets | - | - | - | 0.06M | 0.22M |
| Net receivables | 0.04M | 0.34M | - | 0.02M | 0.02M |
| Accounts payable | 0.37M | 0.25M | 0.08M | 0.04M | 0.05M |
| Accumulated other comprehensive income | 0.25M | 0.05M | - | - | - |
| Non currrent assets other | - | 0.00M | - | - | - |
| Non current assets total | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2021-03-31 |
| Investments | 0.00M | -0.00M | -0.00M | 0.20M | - |
| Change to liabilities | - | - | - | 0.24M | 0.39M |
| Total cashflows from investing activities | - | -0.00M | - | 0.22M | 0.22M |
| Total cash from financing activities | 0.66M | - | 3.50M | 0.78M | 1.96M |
| Net income | -1.59M | -1.63M | -1.34M | -0.99M | -0.65M |
| Change in cash | -0.41M | -1.67M | 2.13M | 0.23M | 1.53M |
| Begin period cash flow | 0.68M | 2.36M | 0.22M | -0.01M | - |
| End period cash flow | 0.28M | 0.68M | 2.36M | 0.22M | - |
| Total cash from operating activities | -1.08M | -1.66M | -1.37M | -0.75M | -0.44M |
| Issuance of capital stock | 0.66M | 0.00M | 3.76M | 0.78M | - |
| Depreciation | 0.00M | 0.00M | 0.00M | - | - |
| Change to account receivables | 0.26M | -0.13M | - | -0.05M | -0.18M |
| Other cashflows from financing activities | - | -0.00M | -0.26M | 0.20M | - |
| Change to netincome | - | - | - | 0.08M | 0.08M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.50M | -0.03M | -0.18M | 0.17M | - |
| Stock based compensation | 0.00M | 0.00M | 0.07M | 0.02M | - |
| Other non cash items | - | 0.13M | 0.07M | 0.05M | - |
| Free cash flow | -1.08M | -1.66M | -1.37M | -0.75M | - |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(GBX) |
Price
(GBX) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| GENF Genflow Biosciences plc |
-0.07 3.95% |
1.82 | - | - | 6.70 | 4.67 | -0.56 |
| GNS Genus PLC |
18.00 0.78% |
2340.00 | 36.08 | 26.18 | 2.53 | 3.46 | 15.38 |
| ONT Oxford Nanopore Technologies Ltd |
10.60 4.93% |
225.60 | - | - | 4.71 | 2.50 | -8.89 |
| OXB Oxford BioMedica PLC |
5.00 0.95% |
532.00 | - | 208.33 | 4.05 | 7.60 | 308.96 |
| AVCT Avacta Group PLC |
-1.00 1.60% |
61.50 | - | - | 2849.46 | 1929.84 | -12.04 |
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducing the incidence of age-related diseases. Its lead drug candidate is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-1003, a topical delivery of SIRT6 to the fibroblasts in the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005, which addresses mitochondrial dysfunction observed in sarcopenia for muscle health and combat sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company has collaborative research agreements with Revatis SA and EXO Biologics for therapy medicinal products. Genflow Biosciences plc was founded in 2020 and is headquartered in London, the United Kingdom.
| Name | Title | Year Born |
|---|---|---|
| Dr. Eric Jean Leire M.D., MBA | Founder, CEO & Exec. Director | 1958 |
| Dr. Cedric Szpirer | Head of CMC | NA |
| Dr. Eric Jean Leire M.D., MBA | Founder, CEO & Executive Director | 1958 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-2.08%
Communication Services
-0.42%
Consumer Cyclical
-0.25%
Consumer Defensive
+0.37%
Energy
-0.13%
Financial Services
-0.90%
Financials
+2.38%
Healthcare
-1.56%
Industrials
-1.07%
Real Estate
-0.26%
Technology
-3.38%
Utilities
-0.36%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...